shortagewatch

Home / Companies / Tatsumi Kagaku

Company family · HQ JP

Tatsumi Kagaku: medicine shortages

As of 2 Nov 2026, 38 Tatsumi Kagaku products have a reported shortage across 1 countries, covering 24 medicines.

Products short38rank #55 of 464
Medicines24active ingredients
Countries1/16
New in 90 days10-5 vs market pace
Typical duration9 monthsmedian so far
Manufacturing63%demand-driven 8%

Where

Japan38

Which therapeutic classes

Cardiovascular system9Nervous system7Digestive tract and metabolism6Anti-infectives5Respiratory system3Sensory organs2Musculoskeletal system1Genito-urinary system and sex hormones1Blood1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Tatsumi KagakuTatsumi Kagaku: Manufacturing problem 24 (69%)69%Tatsumi Kagaku: Increased demand 3 (9%)9%Tatsumi Kagaku: Active ingredient shortage 1 (3%)Tatsumi Kagaku: Regulatory or licensing 1 (3%)Tatsumi Kagaku: Other 6 (17%)17%All companiesAll companies: Manufacturing problem 4,896 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,220 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

Latest changes

All changes

No changes recorded yet. Changes are tracked from our daily snapshots.

When its current shortages began

025710Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 2AugSep: 2Oct: 0Nov: 0NovDec: 2Jan ’26: 3Feb: 1FebMar: 0Apr: 0May: 0MayJun: 8Jul: 0Aug: 0AugSep: 5Oct: 5Nov: 0Nov

Against its peers

Viatris995Teva903Sandoz603Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Tatsumi Kagaku38

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 603 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 150 / 73Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Tatsumi Kagaku: 38 / 24Tatsumi Kagaku

Further right: more products short. Higher: more different medicines affected.

Medicines short

Download CSV
MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Amoxicillin313 Mar 2024Increased demand7/16
Glimepiride325 Jun 2026Manufacturing problem5/16
Nitrazepam318 Feb 2026Manufacturing problem1/16
Amlodipine222 Jan 2026Manufacturing problem8/16
Irbesartan and Amlodipine222 Jan 2026Manufacturing problem1/16
Metformin25 Dec 2025Other8/16
Mirtazapine219 Aug 2025Manufacturing problem10/16
Rosuvastatin225 Jun 2026Manufacturing problem12/16
Carbocisteine112 May 2023Manufacturing problem1/16
Carvedilol12 Sep 2025Manufacturing problem8/16
Cefaclor12 Sep 2025Regulatory or licensing4/16
Clarithromycin112 May 2023Manufacturing problem5/16
Diclofenac125 Jun 2026Quality problem or recall8/16
Eperisone118 Sep 2026Manufacturing problem1/16
Etizolam112 May 2023Manufacturing problem1/16
Famotidine115 Oct 2026Other4/16
Ibuprofen111 Jan 2024Manufacturing problem1/16
Levofloxacin15 Oct 2026Quality problem or recall2/16
Mecobalamin116 Oct 2024Manufacturing problem1/16
Montelukast19 Jul 2024Manufacturing problem13/16
Propiverine18 Jun 2023Quality problem or recall2/16
Telmisartan125 Jun 2026Manufacturing problem6/16
Triazolam119 Aug 2025Other2/16
Valsartan and Amlodipine115 Oct 2026Manufacturing problem5/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.